ArticleNeurology(R) neuroimmunology & neuroinflammation2014
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03345537 (Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis), which is not on this map. Cited by 98 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis (ON) Associated or Not With Autoantibodies Anti- Myelin-oligodendrocyte-glycoprotein (MOG-Ab)
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 224 citations in OpenAlex.
- Double-Negative Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.Neurology(R) neuroimmunology & neuroinflammation · 2026Pooled it
- COVID-19 and the risk of CNS demyelinating diseases: A systematic review.Frontiers in neurology · 2022Pooled it
- Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2019Trial
- Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.JAMA ophthalmology · 2018Trial
- Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.Neurology · 2026Review
- MOGAD in South Wales: Diagnostic Evolution and Disease Epidemiology.European journal of neurology · 2026Article
- Novel B-Cell targeting therapy with subcutaneous ofatumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.Frontiers in immunology · 2026Article
- Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm.BMC neurology · 2025Article
- Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients.Scientific reports · 2025Article
- Antibodies to myelin oligodendrocyte glycoprotein in optic perineuritis.Frontiers in immunology · 2025Article
- Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- MOG antibody-associated optic neuritis.Eye (London, England) · 2024Review
- The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Clinical features of COVID-19-related optic neuritis: a retrospective study.Frontiers in neurology · 2024Article
- Double-negative neuromyelitis optica spectrum disorder.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- MRI pattern in acute optic neuritis: Comparing multiple sclerosis, NMO and MOGAD.The neuroradiology journal · 2023Article
- Evolution in anti-myelin oligodendrocyte glycoprotein antibody detection and its clinical significance: a narrative review.Annals of translational medicine · 2023Review
- Basic CSF parameters and MRZ reaction help in differentiating MOG antibody-associated autoimmune disease versus multiple sclerosis.Frontiers in immunology · 2023Article
- Delimiting MOGAD as a disease entity using translational imaging.Frontiers in neurology · 2023Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe examined a cohort of adults with aquaporin-4 (AQP4) antibody-negative neuromyelitis optica/neuromyelitis optica spectrum disorder (NMO/NMOSD) for antibodies to myelin oligodendrocyte glycoprotein (MOG).
methodsWe performed a flow cytometry cell-based assay using live human lentivirus-transduced cells expressing full-length surface MOG. Serum was tested in 23 AQP4 antibody-negative NMO/NMOSD patients with bilateral and/or recurrent optic neuritis (BON, n = 11), longitudinally extensive transverse myelitis (LETM, n = 10), and sequential BON and LETM (n = 2), as well as in patients with multiple sclerosis (MS, n = 76) and controls (n = 52).
resultsMOG antibodies were detected in 9/23 AQP4 antibody-negative patients with NMO/NMOSD, compared to 1/76 patients with MS and 0/52 controls (p < 0.001). MOG antibodies were detected in 8/11 patients with BON, 0/10 patients with LETM, and 1/2 patients with sequential BON and LETM. Six of 9 MOG antibody-positive patients had a relapsing course. MOG antibody-positive patients had prominent optic disc swelling and were more likely to have a rapid response to steroid therapy and relapse on steroid cessation than MOG antibody-negative patients (p = 0.034 and p = 0.029, respectively). While 8/9 MOG antibody-positive patients had good follow-up visual acuity, one experienced sustained visual impairment, 3 had retinal nerve fiber layer thinning, and one had residual spinal disability.
conclusionsMOG antibodies have a strong association with BON and may be a useful clinical biomarker. MOG antibody-associated BON is a relapsing disorder that is frequently steroid responsive and often steroid dependent. Failure to recognize the disorder early and institute immunotherapy promptly may be associated with sustained impairment. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that MOG antibodies are associated with AQP4 antibody-negative BON (sensitivity 69%, 95% confidence interval [CI] 42%-87%; specificity 99%, 95% CI 93.7%-99.8%).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.